COVID-19 in patients with IBD {#cesec10}
=============================

In addition to increasing age and comorbidities, the use of systemic corticosteroids in patients with inflammatory bowel diseases (IBD) may also be associated with severe COVID-19, but the use of tumour necrosis factor (TNF) antagonists is not, according to an analysis of the SECURE-IBD database. Of 525 cases of COVID-19 in patients with IBD reported, 37 (7%) patients had severe COVID-19, 161 (31%) were hospitalised, and 16 (3%) died. Of the 161 patients hospitalised, 24 (5%) required intensive care and 21 (4%) required ventilation. After adjusting for age, the standardised mortality ratios were 1·8 (95% CI 0·9--2·6) for China, 1·5 (95% CI 0·7--2·2) for Italy, and 1·7 (95% CI 0·9--2·5) for the USA. Risk factors for severe COVID-19 were increasing age (adjusted odds ratio 1·04, 95% CI 1·01--1·06), two or more comorbidities (2·9, 1·1--7·8), systemic corticosteroids (6·9, 2·3--20·5), and sulfasalazine or 5-aminosalicylate use (3·1, 1·3--7·7); no association was observed with TNF antagonist treatment (0·9, 0·4--2·2).

IMbrave150 {#cesec20}
==========

Atezolizumab plus bevacizumab results in better overall and progression-free survival than sorafenib in patients with advanced unresectable hepatocellular carcinoma, according to a global phase 3 trial. Richard Finn and colleagues randomly assigned patients who had not previously received systemic treatment to receive either atezolizumab plus bevacizumab (n=336) or sorafenib (n=165) until unacceptable toxic effects occurred or there was a loss of clinical benefit. 96 (29%) patients in the atezolizumab--bevacizumab group and 65 (39%) in the sorafenib group died (hazard ratio \[HR\] for death 0·58, 95% CI 0·42--0·79; p\<0·001). At 12 months, overall survival was 67·2% (95% CI 61·3--73·1) in the atezolizumab plus bevacizumab group versus 54·6% (45·2--64·0) in the sorafenib group. Median progression-free survival was 6·8 months (95% CI 5·7--8·3) in the atezolizumab plus bevacizumab group versus 4·3 months (4·0--5·6) in the sorafenib group (HR for disease progression or death 0·59, 95% CI 0·47--0·76; p\<0·001). Adverse events of grade 3 or 4 were observed in 186 (57%) of 329 patients who received at least one dose of atezolizumab plus bevacizumab and in 86 (55%) of 156 patients who received at least one dose of sorafenib.

Ivosidenib for *IDH1*-mutant cholangiocarcinoma {#cesec30}
===============================================

Ivosidenib is safe and beneficial in patients with previously treated *IDH1*-mutant cholangiocarcinoma, new research suggests. Ghassan Abou-Alfa and colleagues randomly assigned patients with histologically confirmed, advanced, *IDH1*-mutant cholangiocarcinoma who had progressed on previous therapy to receive oral ivosidenib 500 mg (n=124) or placebo (n=61) once daily in continuous 28-day cycles. Median progression-free survival was 2·7 months (95% CI 1·6--4·2) in the ivosidenib group compared with 1·4 months (1·4--1·6) for placebo (HR 0·37, 95% CI 0·25--0·54; one-sided p\<0·0001). Serious adverse events were reported in 36 (30%) of 121 patients receiving ivosidenib and 13 (22%) of 59 patients receiving placebo. There were no treatment-related deaths.

Motorised spiral enteroscopy {#cesec40}
============================

Motorised spiral enteroscopy is easier and quicker than traditional methods of deep enteroscopy, new research suggests. Torsten Beyna and colleagues consecutively enrolled 132 patients with suspected small bowel disease, in whom 140 procedures were performed. Overall diagnostic yield was 74·2% (98/132) and included arteriovenous malformations, polyps or neoplastic lesions, and inflammatory lesions. 95 endoscopic interventions were performed in 90 procedures, with a therapeutic yield of antegrade motorised spiral enteroscopy of 68·2%. Procedure-related adverse events were observed in 19 (14%) patients; deep mucosal tears were seen in three patients (two in the small bowel, one in the upper oesophagus), all of whom were clinically asymptomatic. Two (2%) serious adverse events occurred; one delayed perforation and one bleeding from Mallory-Weiss lesion.

Capsid assembly modulator for HBV {#cesec50}
=================================

A phase 1 study suggests that JNJ-56136379 (JNJ-6379), a capsid assembly modulator that blocks hepatitis B virus (HBV) replication, could be a promising option for patients with chronic HBV infection. Fabien Zoulim and colleagues randomly assigned treatment-naive patients with chronic HBV infection without cirrhosis to receive JNJ-6379 25 mg (100 mg loading dose), 75 mg, 150 mg, 250 mg, or placebo daily for 4 weeks with an 8-week follow-up period. 23 (56%) of 41 patients in all groups that received JNJ-6379 had at least one adverse event compared with 10 (63%) of 16 in the placebo group. No serious adverse events were observed. HBV DNA and HBV RNA decreased from baseline with all doses of JNJ-6379. 13 (32%) of 41 patients had levels of HBV DNA below the lower limit of quantification when assessed at day 29; no clinically significant changes in levels of HBsAg were noted.
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